Testing to no avail? the diagnostic and treatment conundrum in patients with extraesophageal manifestations of gastroesophageal reflux disease
Editorial

Testing to no avail? the diagnostic and treatment conundrum in patients with extraesophageal manifestations of gastroesophageal reflux disease

Rishi D. Naik, Dhyanesh A. Patel, Michael F. Vaezi

Division of Gastroenterology, Hepatology, and Nutrition, Center for Swallowing and Esophageal Disorders, Vanderbilt University Medical Center, Nashville, TN, USA

Correspondence to: Michael F. Vaezi, MD, PhD, MSc (Epi). Division of Gastroenterology and Hepatology, Center for Swallowing and Esophageal Disorders, Digestive Disease Center, Vanderbilt University Medical Center, 1660 TVC, Nashville, TN 37232-5280, USA. Email: Michael.vaezi@vanderbilt.edu.

Provenance: This is an invited Editorial commissioned by Editor-in-Chief Minhua Zheng (Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Minimal Invasive Surgery, Shanghai, China).

Comment on: Sidhwa F, Moore A, Alligood E, et al. Diagnosis and Treatment of the Extraesophageal Manifestations of Gastroesophageal Reflux Disease. Ann Surg 2017;265:63-7.


Received: 14 August 2017; Accepted: 18 August 2017; Published: 13 September 2017.

doi: 10.21037/ales.2017.08.06


Extraesophageal reflux (EER), which includes cough, asthma, and laryngopharyngeal reflux (LPR), is an important and prevalent disease state with a large economic burden of up to fifty billion dollars, largely due to the pharmaceutical costs of empiric treatment (1). Patients with presumed EER are often treated with empiric acid suppressive therapy (AST), but if symptoms remain refractory, they are then referred for further testing. Despite advent of ambulatory reflux monitoring and impedance testing, diagnostic testing in this population have poor test characteristics with suboptimal sensitivity and specificity (2,3). Esophagogastroduodenoscopy (EGD) is specific for GERD, but lacks sensitivity (less than 30%) due to lack of overt esophagitis in some patients with GERD. Ambulatory pH testing and intraluminal impedance are gold standard for diagnostics, but are also limited due to a limited period of testing, which is often challenged by patient comfort and compliance with intranasal catheter (4). The presence of dilated intracellular spaces (DIS) has been suggested as a marker of chronicity in patients with GERD both with esophagitis and non-erosive GERD, but there remains uncertainty on optimal biopsy, need for costly EGD, and the use of transmission electron microscopy limiting the applicability of this test (5). Mucosal impedance (MI) uses indirect measurements of mucosal conductivity and studies have shown lower intraluminal impedance in patients with GERD compared to controls (6). Finally, in highly selected patients, surgery can be performed for treatment of EER, where symptom relief after surgery can confirm a diagnosis of EER though conclusions are limited by lack of high quality randomized control studies as recently published by this group (7).

In this article in the Annals of Surgery, Sidhwa et al. performed a review of 271 articles with 128 meeting their study criteria to ask three important questions: (I) how are extraesophageal manifestations of reflux diagnosed? (II) What is the effect of medical therapy? and (II) what is the effect of surgical therapy? (8). In evaluating the triumvirate of cough, asthma, and LPR, the authors found that there is lack of diagnostic criterion for all three diseases. Patients with suspected EER associated symptoms initially undergo a PPI-trial ranging from 8 to 16 weeks with improvement in symptoms indicating GERD as the underlying etiology. In patients that are unresponsive to PPI trial, further testing including multichannel intraluminal impedance with pH (MII-pH) might be helpful in determining if reflux might be a contributing factor in this difficult group of patients. Authors also suggest that symptom association probability (SAP) determined by the association of reflux events defined by MII-pH and self-reported cough might be helpful with a specificity of 82% in one study (9). However, clinical utility of SAP is very limited. We would suggest the readers to review important data in this regard about lack of reliability on SAP in patients with cough (10-12). Symptom associations are problematic and should not be used to make important clinical decisions in patients with EER symptoms because patients often do not push the symptom button when they have symptoms and most patients with chronic cough have symptoms related to hypersensitivity rather than GERD related etiology (10,13). Thus, given the low predictive value of pH testing and the lack of reliability of SI and SAP, the use of pH testing in patients with chronic cough is discouraged (14). Diagnosis of EER is fought with great uncertainty due to lack of gold standard test, which has resulted in difficulties in proper study enrollment limiting the robustness of data from the current trials. Sidhwa et al. delineate this problem when discussing the current randomized controls studies, where they point out that there may be a large amount of patients without EER enrolled in the disease arm of these studies biasing the trials towards a type II error.

An important theme resonates on treatment response for EER, which is that patients with concomitant typical GERD symptoms or positive pH monitoring may response to therapy better than those without concomitant GERD symptoms (15,16). Prior evaluation of patients with EER have shown that both heartburn with or without regurgitation and esophageal pH <4 more than 12% of a 24-hour period predicted post-fundoplication resolution of the presenting EER related symptom (12). These findings were expanded on by a recent retrospective cohort study of 115 patients (79 with GERD, 36 with EER) who were evaluated for an average of 66 months after antireflux surgery (ARS), where efficacy of ARS was related to response to AST and less predictable with those having primarily EER symptoms (17).

Sidhwa et al. should be applauded for their work evaluating the current body of literature on EER. A common theme resounded through this analysis involving the lack of high quality randomized control studies despite the prevalence of this disease and number of anti-reflux surgeries performed. Overall, the authors appropriately point out the difficulty in establishing a true causal link between patients’ presenting extraesophageal symptoms and GERD based on current sub-optimal diagnostic testing. One novel technology which may be helpful in this area, though not well studied, is MI. In patients with symptoms of EER and evidence of acid reflux, MI values are lower than those without EER showing that MI may be used a tool to detect the presence of GERD in patients presenting with EER associated symptoms (18). In addition to further high quality studies, the role of this modality should continue to be investigated.

Current guidelines on management of EER are highly dependent on the society evaluating the literature with variation in management of cough, asthma, and LPR. The authors state referral for ARS for LPR and asthma, though caution should be advised to the patients on the potential lack of benefit. We would support a more vigorous screening based on the aforementioned studies on response to AST and concomitant typical GERD symptoms to help define referral patterns for ARS to improve success rate of symptom control as defined by symptom recurrence post-surgery.

Thus, EER is a commonly encountered clinical problem for many gastroenterologist and surgeons and has a large economic burden partly due to indiscriminate use of long term PPI therapy. We would urge the readers to question the utility of high dose PPI therapy after 2-month of empiric therapy. If patients report improvement of extraesophageal symptoms with AST, tapering to once daily and eventually leaving patient on the lowest effective dose of AST is recommended. Diagnostic testing in this group can only be employed as surrogate markers for GERD and doesn’t necessarily imply response to anti-reflux therapy, medications or surgery. We urge the readership to avoid the use of symptom association alone in assessing possible link between GERD and EER. ARS is an important management technique for those with EER; however, strict selection should be performed to avoid unnecessary surgery in those who may not truly have reflux related symptoms.


Acknowledgements

None.


Footnote

Conflicts of Interest: Vanderbilt University along with Sandhill Scientific are co-patent owners for the mucosal impedance device discussed in this article.


References

  1. Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol 2013;108:905-11. [Crossref] [PubMed]
  2. Naik RD, Vaezi MF. Recent advances in diagnostic testing for gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 2017;11:531-7. [Crossref] [PubMed]
  3. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308-28. [Crossref] [PubMed]
  4. Vaezi MF, Schroeder PL, Richter JE. Reproducibility of proximal probe pH parameters in 24-hour ambulatory esophageal pH monitoring. Am J Gastroenterol 1997;92:825-9. [PubMed]
  5. Vaezi MF, Slaughter JC, Smith BS, et al. Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy. Aliment Pharmacol Ther 2010;32:916-24. [Crossref] [PubMed]
  6. Farre R, Blondeau K, Clement D, et al. Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. Gut 2011;60:885-92. [Crossref] [PubMed]
  7. Sidwa F, Moore AL, Alligood E, et al. Surgical Treatment of Extraesophageal Manifestations of Gastroesophageal Reflux Disease. World J Surg 2017. [Epub ahead of print]. [Crossref] [PubMed]
  8. Sidhwa F, Moore A, Alligood E, et al. Diagnosis and Treatment of the Extraesophageal Manifestations of Gastroesophageal Reflux Disease. Ann Surg 2017;265:63-7. [Crossref] [PubMed]
  9. Hersh MJ, Sayuk GS, Gyawali CP. Long-term therapeutic outcome of patients undergoing ambulatory pH monitoring for chronic unexplained cough. J Clin Gastroenterol 2010;44:254-60. [Crossref] [PubMed]
  10. Kavitt RT, Higginbotham T, Slaughter JC, et al. Symptom reports are not reliable during ambulatory reflux monitoring. Am J Gastroenterol 2012;107:1826-32. [Crossref] [PubMed]
  11. Slaughter JC, Goutte M, Rymer JA, et al. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2011;9:868-74. [Crossref] [PubMed]
  12. Francis DO, Goutte M, Slaughter JC, et al. Traditional reflux parameters and not impedance monitoring predict outcome after fundoplication in extraesophageal reflux. Laryngoscope 2011;121:1902-9. [PubMed]
  13. Francis DO, Slaughter JC, Ates F, et al. Airway Hypersensitivity, Reflux, and Phonation Contribute to Chronic Cough. Clin Gastroenterol Hepatol 2016;14:378-84. [Crossref] [PubMed]
  14. Smith JA, Decalmer S, Kelsall A, et al. Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology 2010;139:754-62. [Crossref] [PubMed]
  15. Fernando HC, El-Sherif A, Landreneau RJ, et al. Efficacy of laparoscopic fundoplication in controlling pulmonary symptoms associated with gastroesophageal reflux disease. Surgery 2005;138:612-6; discussion 6-7. [Crossref] [PubMed]
  16. Swoger J, Ponsky J, Hicks DM, et al. Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol 2006;4:433-41. [Crossref] [PubMed]
  17. Krill JT, Naik RD, Higginbotham T, et al. Association Between Response to Acid-Suppression Therapy and Efficacy of Antireflux Surgery in Patients With Extraesophageal Reflux. Clin Gastroenterol Hepatol 2017;15:675-81. [Crossref] [PubMed]
  18. Kavitt RT, Lal P, Yuksel ES, et al. Esophageal Mucosal Impedance Pattern is Distinct in Patients With Extraesophageal Reflux Symptoms and Pathologic Acid Reflux. J Voice 2017;31:347-51. [Crossref] [PubMed]
doi: 10.21037/ales.2017.08.06
Cite this article as: Naik RD, Patel DA, Vaezi MF. Testing to no avail? the diagnostic and treatment conundrum in patients with extraesophageal manifestations of gastroesophageal reflux disease. Ann Laparosc Endosc Surg 2017;2:143.

Refbacks

  • There are currently no refbacks.